AcelRx Pharmaceuticals Q3 2023 Gaap EPS $(0.08) Beats $(0.28) Estimate, Sales $117.00K Miss $130.00K Estimate
Portfolio Pulse from saritha@benzinga.com
AcelRx Pharmaceuticals reported Q3 2023 GAAP EPS of $(0.08), beating the estimate of $(0.28) by 71.43%. However, the company's sales of $117.00K missed the estimate of $130.00K by 10.00%. This represents a 91.49% increase in EPS and a 76.92% decrease in sales compared to the same period last year.
November 08, 2023 | 10:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AcelRx Pharmaceuticals' Q3 2023 results beat EPS estimates but missed on sales. This could lead to mixed market reactions.
AcelRx Pharmaceuticals reported better than expected earnings per share, which could positively impact the stock. However, the company missed sales estimates, which could negatively affect the stock. The net effect could be neutral, leading to mixed market reactions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100